Mezzion Pharma메지온
140410 · KOSDAQ · ₩140410 · 메지온
₩52,600 ₩0 (0.00%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — |
| Operating margin | −223.1% | −212.0% | −166.0% | −45.7% | −75.9% | −63.0% |
| Net margin | −325.0% | −441.6% | −226.2% | −40.1% | −118.1% | −51.0% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +6.6% | −8.2% | −72.9% | +3.2% | +15.3% | — |
| Operating income growth | −12.2% | −17.3% | +1.3% | +37.9% | −38.9% | — |
| Net income growth | +21.6% | −79.3% | −53.0% | +64.9% | −166.8% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −97.4% | −110.4% | −36.2% | −29.0% | −81.5% | −21.7% |
| Return on assets | −24.5% | −40.6% | −23.4% | −17.4% | −52.6% | −16.2% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 220.8% | 470.1% | 60.6% | 50.0% | 105.9% | 33.7% |
| Net debt to equity | −63.3% | −91.1% | — | — | — | — |
| Current ratio | 68.2% | 57.3% | 157.2% | 250.7% | 176.0% | 347.0% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Mezzion Pharma / 메지온 / 140410 / KRX:140410
Source: KRX statistical information